SAVIENT PHARMACEUTICALS, INC. ALERT: SAVIENT PHARMACEUTICALS, INC. BANKRUPTCY - GOODMAN & NEKVASIL, P.A., RECOVERING INVESTOR LOSSES
Goodman & Nekvasil, P.A., Recovering Investor Losses - Savient Pharmaceuticals, Inc. Alert: Savient Pharmaceuticals, Inc. Bankruptcy
Goodman & Nekvasil, P.A., a Clearwater, Florida, law firm with a national practice representing victimized investors, continues to investigate brokerage firms that placed elderly retirees and other conservative investors in high-risk investments, including Savient Pharmaceuticals, Inc.
On August 14, 2013, Savient Pharmaceuticals, Inc. said in Savient Pharmaceuticals, Inc.’s 10Q filing for the second quarter: “We believe that our available cash, cash equivalents, and short-term investments, which includes the net proceeds of the transactions discussed above, will be sufficient to fund anticipated levels of operations for at least the next twelve months from the date hereof.” But in October 2013, only two months later, Savient Pharmaceuticals, Inc. filed for Chapter 11 bankruptcy.
Even though high yield or junk bonds, notes, limited partnership units, and stock issued by Savient Pharmaceuticals, Inc. have considerable risk, overzealous brokers, brokerage firms and registered investment advisors have nonetheless recommended Savient Pharmaceuticals, Inc. and these types of investments to conservative investors seeking income. We believe that investors in Savient Pharmaceuticals, Inc. lost a significant amount of their savings when Savient Pharmaceuticals, Inc. filed for bankruptcy.
Goodman & Nekvasil, P.A., has filed hundreds of cases against brokerage firms selling high-risk investments such as Savient Pharmaceuticals, Inc., and has recovered more than $170 million dollars on behalf of victimized investors. We allege in these cases that these investment recommendations were unsuitable for our clients in view of their financial situation, needs and investment objectives. All our cases are handled on a purely contingency fee basis.
You may have the right to recover your losses from the brokerage firm that sold Savient Pharmaceuticals, Inc. and other high-risk investments to you. We strongly recommend that you act quickly, however, because statutes of limitation can be short in securities cases.
Kalju Nekvasil, Esq., formerly regional counsel with the NASD, now known as FINRA, has practiced in this area of the law for more than 35 years. We would like to discuss the possibility of your retaining our firm to represent you in an arbitration action.
There is no charge for an evaluation of your case. Further, we handle our cases on a contingency fee basis. This means that unless we recover money for you, we charge no attorney’s fee. Unless you recover any money, you pay us nothing, not even the costs and expenses which the firm will advance on your behalf. Finally, the filing of such a case should not affect your rights as a creditor in the Savient Pharmaceuticals, Inc. bankruptcy or your ownership of these investments in any way.
If you incurred losses on your investment in Savient Pharmaceuticals, Inc. and/or other high-risk investments and would like your case evaluated by a securities attorney (again, there is no charge for an evaluation and all cases are handled on a purely contingency fee basis), please contact us.
Keywords: Savient, Savient Pharmaceuticals, Pharma, Investment, Bankruptcy, Goodman and Nekvasil, Nekvasil, Goodman, Securities, Securities Attorney, Attorney, Lawyer,Back to Blogs